
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1178232/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 106-115.	7.0	18
2	Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer in Asian breast cancer Research and Treatment, 2022, 192, 629-637.	2.5	6
3	Abstract P2-10-09: Oxysterol profiling in breast adipose tissue identifies brassicasterol and 24-hydroxycholesterol as breast cancer risk predictors. Cancer Research, 2022, 82, P2-10-09-P2-10-09.	0.9	0
4	Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies. Cancer Research, 2022, 82, P5-13-18-P5-13-18.	0.9	0
5	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. Cancer Research, 2022, 82, PD2-05-PD2-05.	0.9	2
6	Abstract P2-01-09: Clinical impact of ESR1 mutation ctDNA on survival outcome is dependent on PI3KCA/TP53 ctDNA mutation status. Cancer Research, 2022, 82, P2-01-09-P2-01-09.	0.9	0
7	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Medicine, 2022, 20, 105.	5.5	60
8	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2â° Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 2022, 28, 851-859.	7.0	90
9	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 408-417.	7.0	21
10	Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 669-678.	2.8	16
11	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 418-428.	7.0	16
12	A phase lb/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Research, 2021, 23, 8.	5.0	15
13	Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. Therapeutics and Clinical Risk Management, 2021, Volume 17, 193-207.	2.0	34
14	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. Clinical and Translational Science, 2021, 14, 1015-1025.	3.1	2
15	BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd) Journal of Clinical Oncology, 2021, 39, 1023-1023.	1.6	49
16	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. Npj Breast Cancer, 2021, 7, 88.	5.2	8
17	Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precision Oncology, 2021, 5, 1408-1420.	3.0	15
18	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Research and Treatment, 2021, 189, 665-676.	2.5	15

#	Article	IF	CITATIONS
19	Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. Frontiers in Oncology, 2021, 11, 700722.	2.8	12
20	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. Targeted Oncology, 2021, 16, 701-741.	3.6	7
21	Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients. Breast, 2021, 59, 211-220.	2.2	2
22	Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2â^' Advanced Breast Cancer. Cancer Management and Research, 2021, Volume 13, 8179-8189.	1.9	2
23	Response to Sung, Rosenberg, and Yang. Journal of the National Cancer Institute, 2020, 112, 547-548.	6.3	0
24	Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women. Oncologist, 2020, 25, e252-e258.	3.7	4
25	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 2020, 38, 3138-3149.	1.6	355
26	Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094306.	3.2	44
27	A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. Environment International, 2020, 142, 105850.	10.0	48
28	Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. Oncologist, 2020, 25, e16-e23.	3.7	40
29	Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival. Journal of Neuro-Oncology, 2020, 148, 165-172.	2.9	17
30	Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials Journal of Clinical Oncology, 2020, 38, 1009-1009.	1.6	34
31	CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC) Journal of Clinical Oncology, 2020. 38. TPS1111-TPS1111.	1.6	2
32	Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence Journal of Clinical Oncology, 2020, 38, TPS599-TPS599.	1.6	6
33	Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial Journal of Clinical Oncology, 2020, 38, 1082-1082.	1.6	0
34	Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. Scientific Reports, 2019, 9, 10898.	3.3	5
35	Treating HR+/HER2â [~] ' breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Research and Treatment, 2019, 177, 549-559.	2.5	29
36	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncology, 2019, 15, 2489-2501.	2.4	8

#	Article	IF	CITATIONS
37	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019, 381, 307-316.	27.0	656
38	Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine, 2019, 380, 1929-1940.	27.0	1,582
39	Insights Into Breast Cancer in the East vs the West. JAMA Oncology, 2019, 5, 1489.	7.1	90
40	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. Journal of the National Cancer Institute, 2019, 111, 1298-1306.	6.3	83
41	PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. Journal of the Formosan Medical Association, 2019, 118, 1333-1338.	1.7	24
42	In-depth gene expression analysis of premenopausal patients with HR+/HER2â^' advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial Journal of Clinical Oncology, 2019, 37, 1018-1018.	1.6	5
43	Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients Journal of Clinical Oncology, 2019, 37, 1084-1084.	1.6	5
44	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2â^' advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results Journal of Clinical Oncology, 2019, 37, LBA1008-LBA1008.	1.6	19
45	The interplay of adiposity, metabolic factors, and tumor infiltrating lymphocytes in an East Asian breast cancer cohort Journal of Clinical Oncology, 2019, 37, e14207-e14207.	1.6	0
46	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Analytica Chimica Acta, 2018, 1019, 93-102.	5.4	50
47	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology, 2018, 48, 242-247.	1.3	4
48	Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. Cancer Prevention Research, 2018, 11, 227-236.	1.5	31
49	Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer. European Radiology, 2018, 28, 4860-4870.	4.5	9
50	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 904-915.	10.7	648
51	Effect of glucocorticoid use on survival in patients with stage l–III breast cancer. Breast Cancer Research and Treatment, 2018, 171, 225-234.	2.5	8
52	Association of pregnancy and mortality in women diagnosed with breast cancer: A Nationwide Population Based Study in Taiwan. International Journal of Cancer, 2018, 143, 2416-2424.	5.1	14
53	Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis Journal of Clinical Oncology, 2018, 36, 1047-1047.	1.6	1
54	Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. Analytical and Bioanalytical Chemistry, 2017, 409, 6583-6593.	3.7	19

YEN-SHEN LU

#	Article	IF	CITATIONS
55	Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. Scientific Reports, 2017, 7, 9842.	3.3	25
56	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	10.7	451
57	Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget, 2016, 7, 8310-8320.	1.8	83
58	Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. European Journal of Cancer, 2016, 60, 107-116.	2.8	8
59	Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1–2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy. Annals of Surgical Oncology, 2016, 23, 3860-3869.	1.5	29
60	Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. Scientific Reports, 2016, 6, 21374.	3.3	17
61	A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer, 2016, 16, 466.	2.6	23
62	Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis. Journal of the Formosan Medical Association, 2016, 115, 243-248.	1.7	17
63	Tailor the adjuvant hormonal manipulation for premenopausal breast cancer patients. Translational Cancer Research, 2016, 5, S380-S384.	1.0	0
64	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. Scientific Reports, 2015, 5, 17879.	3.3	11
65	Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient. Journal of Magnetic Resonance Imaging, 2015, 42, 1407-1420.	3.4	20
66	High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. PLoS ONE, 2015, 10, e0124908.	2.5	9
67	Associations between Medical Conditions and Breast Cancer Risk in Asians: A Nationwide Population-Based Study in Taiwan. PLoS ONE, 2015, 10, e0143410.	2.5	34
68	A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer, 2015, 15, 299.	2.6	56
69	Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clinical Cancer Research, 2015, 21, 1851-1858.	7.0	72
70	Clinical significance of LKB1 protein and gene expression in breast cancer Journal of Clinical Oncology, 2015, 33, e11538-e11538.	1.6	0
71	Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II α, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer Journal of Clinical Oncology, 2015, 33, 1025-1025.	1.6	0
72	Distinct Clinicopathological Features and Prognosis of Emerging Young-Female Breast Cancer in an East Asian Country: A Nationwide Cancer Registry-Based Study. Oncologist, 2014, 19, 583-591.	3.7	44

#	Article	IF	CITATIONS
73	No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. Breast Cancer Research and Treatment, 2014, 148, 135-142.	2.5	11
74	Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology, 2014, 65, 328-339.	2.9	35
75	Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography–electrospray ionization mass spectrometry. Journal of Chromatography A, 2014, 1358, 85-92.	3.7	12
76	Abstract 2984: Normalization of tumor vasculature by anti-angiogenesis therapy in metastatic tumor: A clinical study to determine the timing and effect. Cancer Research, 2014, 74, 2984-2984.	0.9	3
77	Does chemotherapy schedule matter when combining with bevacizumab? A stratified meta-analysis of randomized controlled trials Journal of Clinical Oncology, 2014, 32, 1076-1076.	1.6	2
78	Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. Journal of Neuro-Oncology, 2013, 115, 61-70.	2.9	9
79	The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast, 2013, 22, 1148-1154.	2.2	3
80	Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast carcinoma and its biological significance. Human Pathology, 2013, 44, 1838-1848.	2.0	12
81	Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. Journal of Clinical Pathology, 2013, 66, 140-145.	2.0	15
82	The Impact of Diabetes Mellitus on Prognosis of Early Breast Cancer in Asia. Oncologist, 2012, 17, 485-491.	3.7	37
83	Hashimoto's Encephalopathy As the Cause of Deteriorating Consciousness During Treatment of Leptomeningeal Carcinomatosis From Breast Cancer. Journal of Clinical Oncology, 2012, 30, e358-e359.	1.6	0
84	Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. Journal of Human Genetics, 2012, 57, 130-138.	2.3	21
85	Radiosensitizing Effect of a Phenylbutyrate-Derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, e181-e189.	0.8	22
86	Differential expression of moesin in breast cancers and its implication in epithelial–mesenchymal transition. Histopathology, 2012, 61, 78-87.	2.9	38
87	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. Oncology, 2012, 82, 59-66.	1.9	29
88	Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer, 2012, 12, 620.	2.6	16
89	The emerging epidemic of estrogenâ€related cancers in young women in a developing Asian country. International Journal of Cancer, 2012, 130, 2629-2637.	5.1	47
90	Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study Journal of Clinical Oncology, 2012, 30, 1079-1079.	1.6	19

#	Article	IF	CITATIONS
91	Estimation of maximum tolerated dose and minimum efficient dose of BP-C1 in the treatment of stage IV breast cancer patients: A phase I response surface pathway designed study Journal of Clinical Oncology, 2012, 30, e11022-e11022.	1.6	2
92	The first two lines of chemotherapy for anthracycline-naÃ⁻ve metastatic breast cancer: A comparative study of efficacy between anthracyclines and nonanthracyclines Journal of Clinical Oncology, 2012, 30, 1061-1061.	1.6	0
93	The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer. Academic Radiology, 2011, 18, 212-219.	2.5	7
94	Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Research and Treatment, 2011, 130, 345-351.	2.5	98
95	Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 1257-1263.	2.3	8
96	lκB kinases increase Myc protein stability and enhance progression of breast cancer cells. Molecular Cancer, 2011, 10, 53.	19.2	25
97	Cisplatin as an active treatment in zoledronate-refractory hypercalcemia. Annals of Oncology, 2011, 22, 1244-1246.	1.2	2
98	Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?. Journal of Clinical Pathology, 2011, 64, 781-787.	2.0	10
99	Axillary vs Sentinel Lymph Node Dissection for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 2288.	7.4	6
100	Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. Journal of Zhejiang University: Science B, 2010, 11, 1-9.	2.8	12
101	The prevalence and assessment of ErbB2â \in positive breast cancer in Asia. Cancer, 2010, 116, 5348-5357.	4.1	17
102	Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Japanese Journal of Clinical Oncology, 2010, 40, 286-293.	1.3	27
103	Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib. Japanese Journal of Clinical Oncology, 2010, 40, 999-1013.	1.3	20
104	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer, 2010, 68, 484-490.	2.0	29
105	Unique features of breast cancer in Asian women—Breast cancer in Taiwan as an example. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 300-303.	2.5	42
106	Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Letters, 2010, 298, 195-203.	7.2	20
107	Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1807-1814.	2.5	103
108	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 5820-5828.	7.0	35

#	Article	IF	CITATIONS
109	Locoregional Therapy Improves Survival for Metastatic Breast Cancer Patients? Benefit Remains Questionable!. Journal of Clinical Oncology, 2009, 27, e179-e179.	1.6	1
110	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2009, 284, 11121-11133.	3.4	79
111	Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncology, The, 2009, 10, 1077-1085.	10.7	29
112	Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage l–II and operable stage III Taiwanese breast cancer patients. Breast, 2008, 17, 646-653.	2.2	14
113	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2008, 68, 6698-6707.	0.9	109
114	NF-κB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochemical and Biophysical Research Communications, 2008, 376, 283-287.	2.1	23
115	OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species–Related Autophagy in Hepatocellular Carcinoma. Cancer Research, 2008, 68, 9348-9357.	0.9	131
116	FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C δ Signaling. Cancer Research, 2008, 68, 1204-1212.	0.9	99
117	Histone Deacetylase Inhibitors in Cancer Therapy. , 2008, , 381-398.		0
118	Pneumatosis Coli After Etoposide Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2007, 25, 1623-1625.	1.6	17
119	Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation. Cancer Research, 2007, 67, 5318-5327.	0.9	179
120	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology, 2007, 46, 1119-1130.	7.3	84
121	Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer, 2006, 53, 303-310.	2.0	38
122	Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 874-879.	2.8	9
123	Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. Journal of Endocrinology, 2006, 188, 311-319.	2.6	19
124	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. Oncology, 2005, 69, 88-95.	1.9	19
125	Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World Journal of Gastroenterology, 2005, 11, 5283.	3.3	18
126	Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World Journal of Gastroenterology, 2005, 11, 6373.	3.3	25

#	Article	IF	CITATIONS
127	Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Physics in Medicine and Biology, 2004, 49, 3593-3602.	3.0	74
128	Recent advances in the management of primary breast cancers. Journal of the Formosan Medical Association, 2004, 103, 579-98.	1.7	11
129	Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochemical Pharmacology, 2002, 63, 1709-1716.	4.4	159
130	Phase II trial combining paclitaxel with 24â€hour infusion cisplatin for chemotherapyâ€naÃ⁻ve patients with locally advanced or metastatic breast carcinoma. Cancer, 2002, 95, 2044-2050.	4.1	10
131	Phthalate Exposure, Metabolism Capability, and Breast Cancer Risk: Case-Control Analysis Nested in a Large-Scale Long-Term Follow-Up Cohort. SSRN Electronic Journal, 0, , .	0.4	Ο